The first attempt in synthesis, identification, and evaluation of SEPT9 inhibitors on human oral squamous carcinomas

Bioorg Chem. 2025 Jan:154:108068. doi: 10.1016/j.bioorg.2024.108068.

Hsuan-Yu Lai ¹, Ko-Hua Yu ¹, Keng-Chang Tsai ², Chao-Chang Lee ³, Han-Yu Wang ⁴, Yi-Ping Hsieh ⁵, Kuan-Yi Chiang ⁶, Pao-Lin Kuo ⁷, Tze-Ta Huang ⁸, Hsin-Yi Hung ⁹

Affiliations

1 School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
2 School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan; Ministry of Health and Welfare, National Research Institute of Chinese Medicine, Taipei 112, Taiwan.
3 Ministry of Health and Welfare, National Research Institute of Chinese Medicine, Taipei 112, Taiwan.
4 Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Obstetrics and Gynecology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
5 Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
6 Institute of Oral Medicine, School of Dentistry, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
7 Department of Obstetrics and Gynecology, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.
8 Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Oral Medicine, School of Dentistry, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan; Department of Stomatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan. Electronic address: tzetahuang@mail.ncku.edu.tw.
9 School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan. Electronic address: z10308005@email.ncku.edu.tw.

PMID: 39705938 DOI: 10.1016/j.bioorg.2024.108068

Abstract

Septin 9 (SEPT9), a GTPase, known as the fourth Cytoskeleton, is widely expressed in various cells and tissues. The functions of SEPT9 are partly similar to Other cytoskeletons as a structure protein. Further, SEPT9 can interact with Other cytoskeletons, participating in actin dynamics and microtubule regulation. SEPT9 is associated with various diseases, such as cancers. Thus, it could be a potential drug target. However, there are no small molecule SEPT9 inhibitors and the only reported septin inhibitor, forchlorfenuron, has no effects on SEPT9 inhibition from our study results. Therefore, the derivatives of forchlorfenuron were synthesized, and their activities were evaluated by a direct SEPT9 inhibition screening platform, followed by localized surface plasmon resonance (LSPR) and cell-based assays. The screening results conveyed that 6b, 8a, and 8b are SEPT9 inhibitors with IC₅₀ values of 91, 99, and 95 μM, respectively. Also, their binding affinities were 4, 18, and 22 μM, respectively, validated through LSPR. Eventually, the SAR concludes that at the para position, small substituents are tolerated, while at the ortho position, a bulky benzene ring substituent can be the best candidate. In cell-based assays, the IC₅₀ of 6a, 8a, and 8b of human oral squamous carcinomas cytotoxicity were 122, 20, and 21 µM, respectively. Additionally, significant suppression of the cell migration and invasion ability was observed with the 8b treatment. The co-localization study revealed that 8b effectively disrupted the structural organization of SEPT9, microtubules, and actins. This is the first article to systematically study SEPT9 inhibitors and their biological properties, hoping to shed some light on septin research.

Keywords

Forchlorfenuron; SEPT9; Septin; Structure–activity relationship.

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-170647

SEPT9-IN-1

SEPT9 Inhibitor

Ras

Cancer

Name
Email *

	Sorry, but the email address you supplied was invalid.